Cargando…

A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing

BACKGROUND: BRCA1/2 mutation carriers’ choice between risk‐reducing salpingo‐oophorectomy (RRSO) and salpingectomy with delayed oophorectomy is very complex. Aim was to develop a patient decision aid that combines evidence with patient preferences to facilitate decision making. DESIGN: Systematic de...

Descripción completa

Detalles Bibliográficos
Autores principales: Harmsen, Marline G., Steenbeek, Miranda P., Hoogerbrugge, Nicoline, van Doorn, Helena C., Gaarenstroom, Katja N., Vos, M. Caroline, Massuger, Leon F.A.G., de Hullu, Joanne A., Hermens, Rosella P.M.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980589/
https://www.ncbi.nlm.nih.gov/pubmed/29281161
http://dx.doi.org/10.1111/hex.12661
_version_ 1783327902927945728
author Harmsen, Marline G.
Steenbeek, Miranda P.
Hoogerbrugge, Nicoline
van Doorn, Helena C.
Gaarenstroom, Katja N.
Vos, M. Caroline
Massuger, Leon F.A.G.
de Hullu, Joanne A.
Hermens, Rosella P.M.G.
author_facet Harmsen, Marline G.
Steenbeek, Miranda P.
Hoogerbrugge, Nicoline
van Doorn, Helena C.
Gaarenstroom, Katja N.
Vos, M. Caroline
Massuger, Leon F.A.G.
de Hullu, Joanne A.
Hermens, Rosella P.M.G.
author_sort Harmsen, Marline G.
collection PubMed
description BACKGROUND: BRCA1/2 mutation carriers’ choice between risk‐reducing salpingo‐oophorectomy (RRSO) and salpingectomy with delayed oophorectomy is very complex. Aim was to develop a patient decision aid that combines evidence with patient preferences to facilitate decision making. DESIGN: Systematic development of a patient decision aid in an iterative process of prototype development, alpha testing by patients and clinicians and revisions using International Patient Decision Aid Standards (IPDAS) quality criteria. Information was based on the available literature and current guidelines. A multidisciplinary steering group supervised the process. SETTING AND PARTICIPANTS: Pre‐menopausal BRCA1/2 mutation carriers choosing between RRSO and salpingectomy with delayed oophorectomy in Family Cancer Clinics in the Netherlands. MAIN OUTCOME MEASURES: IPDAS quality criteria, relevance, usability, clarity. RESULTS: The patient decision aid underwent four rounds of alpha testing and revisions. Finally, two paper decision aids were developed: one for BRCA1 and one for BRCA2. They both contained a general introduction, three chapters and a step‐by‐step plan containing a personal value clarification worksheet. During alpha testing, risk communication and information about premature menopause and hormone therapy were the most revised items. The patient decision aids fulfil 37 of 43 (86%) IPDAS criteria for content and development process. DISCUSSION AND CONCLUSIONS: Both BRCA1/2 mutation carriers and professionals are willing to use or offer the developed patient decision aids for risk‐reducing surgery. The patient decision aids have been found clear, balanced and comprehensible. Future testing among patients facing the decision should point out its effectiveness in improving decision making.
format Online
Article
Text
id pubmed-5980589
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59805892018-06-07 A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing Harmsen, Marline G. Steenbeek, Miranda P. Hoogerbrugge, Nicoline van Doorn, Helena C. Gaarenstroom, Katja N. Vos, M. Caroline Massuger, Leon F.A.G. de Hullu, Joanne A. Hermens, Rosella P.M.G. Health Expect Original Research Papers BACKGROUND: BRCA1/2 mutation carriers’ choice between risk‐reducing salpingo‐oophorectomy (RRSO) and salpingectomy with delayed oophorectomy is very complex. Aim was to develop a patient decision aid that combines evidence with patient preferences to facilitate decision making. DESIGN: Systematic development of a patient decision aid in an iterative process of prototype development, alpha testing by patients and clinicians and revisions using International Patient Decision Aid Standards (IPDAS) quality criteria. Information was based on the available literature and current guidelines. A multidisciplinary steering group supervised the process. SETTING AND PARTICIPANTS: Pre‐menopausal BRCA1/2 mutation carriers choosing between RRSO and salpingectomy with delayed oophorectomy in Family Cancer Clinics in the Netherlands. MAIN OUTCOME MEASURES: IPDAS quality criteria, relevance, usability, clarity. RESULTS: The patient decision aid underwent four rounds of alpha testing and revisions. Finally, two paper decision aids were developed: one for BRCA1 and one for BRCA2. They both contained a general introduction, three chapters and a step‐by‐step plan containing a personal value clarification worksheet. During alpha testing, risk communication and information about premature menopause and hormone therapy were the most revised items. The patient decision aids fulfil 37 of 43 (86%) IPDAS criteria for content and development process. DISCUSSION AND CONCLUSIONS: Both BRCA1/2 mutation carriers and professionals are willing to use or offer the developed patient decision aids for risk‐reducing surgery. The patient decision aids have been found clear, balanced and comprehensible. Future testing among patients facing the decision should point out its effectiveness in improving decision making. John Wiley and Sons Inc. 2017-12-27 2018-06 /pmc/articles/PMC5980589/ /pubmed/29281161 http://dx.doi.org/10.1111/hex.12661 Text en © 2017 The Authors Health Expectations published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Papers
Harmsen, Marline G.
Steenbeek, Miranda P.
Hoogerbrugge, Nicoline
van Doorn, Helena C.
Gaarenstroom, Katja N.
Vos, M. Caroline
Massuger, Leon F.A.G.
de Hullu, Joanne A.
Hermens, Rosella P.M.G.
A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
title A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
title_full A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
title_fullStr A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
title_full_unstemmed A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
title_short A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
title_sort patient decision aid for risk‐reducing surgery in premenopausal brca1/2 mutation carriers: development process and pilot testing
topic Original Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980589/
https://www.ncbi.nlm.nih.gov/pubmed/29281161
http://dx.doi.org/10.1111/hex.12661
work_keys_str_mv AT harmsenmarlineg apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT steenbeekmirandap apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT hoogerbruggenicoline apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT vandoornhelenac apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT gaarenstroomkatjan apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT vosmcaroline apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT massugerleonfag apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT dehullujoannea apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT hermensrosellapmg apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT harmsenmarlineg patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT steenbeekmirandap patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT hoogerbruggenicoline patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT vandoornhelenac patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT gaarenstroomkatjan patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT vosmcaroline patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT massugerleonfag patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT dehullujoannea patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting
AT hermensrosellapmg patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting